Related by context. All words. (Click for frequent words.) 84 RECIST 82 Response Evaluation Criteria 80 RECIST Response Evaluation Criteria 79 evaluable patients 77 Solid Tumors RECIST 77 CR CRu 75 evaluable 73 Partial Responses 73 patients evaluable 72 Solid Tumors criteria 71 Partial Response 71 remission CR 71 CCyR 68 partial remissions 68 CRp 68 CR nPR 68 EBMT criteria 68 progression TTP 68 mg/m2 dose 68 biochemical relapse 67 cytogenetic response 67 Complete Response CR 67 complete cytogenetic 66 undetectable HCV RNA 66 complete remissions 66 Kaplan Meier analysis 66 nodular partial response 66 CRu 66 Solid Tumours 66 lymphocytosis 66 chemoradiotherapy 65 underwent surgical resection 65 Kaplan Meier estimate 65 evaluable subjects 65 Rate ORR 65 DAS# CRP 65 HBeAg seroconversion 65 undetectable HBV DNA 65 mg kg dose 65 Index CDAI 65 bortezomib refractory 65 neoadjuvant chemotherapy 64 pegylated interferon alfa 2b 64 relapsed MM 64 median PFS 64 chlorambucil 64 ACR Pedi 64 Solid Tumors 64 achieved CCyR 64 iniparib BSI 64 FOLPI 64 prospectively defined 64 dose escalation phase 64 recurrent glioblastoma multiforme 64 CIMZIA TM 64 free survival PFS 64 % Confidence Interval 64 DAS# remission 64 mg/m2/day 64 histologically confirmed 64 tumor shrinkage 64 locoregional disease 64 pCR 63 MCyR 63 intermittent dosing 63 timepoints 63 mcg albinterferon alfa 2b 63 relapsed MCL 63 locoregional recurrence 63 EDSS scores 63 cEVR 63 Pharmacokinetic parameters 63 sustained virological response 63 Secondary endpoints include 63 dose cohort 63 complete cytogenetic response 63 underwent resection 63 PSA nadir 63 % CI #.#-#.# [003] 63 follicular lymphomas 63 peg interferon 63 heavily pretreated patients 63 Free Survival PFS 63 treatment naive genotype 63 viral kinetics 63 neurologic progression 63 plus dexamethasone 63 FOLFOX4 63 mesalamine granules 63 Crohn Disease Activity 62 NMIBC 62 #mg QD [002] 62 ACR# response 62 FOLFOX 62 surrogate endpoint 62 Flu Cy 62 neoadjuvant therapy 62 Expanded Disability Status 62 % CI #.#-#.# [007] 62 ACTEMRA TM 62 tumor regression 62 biochemical recurrence 62 KRAS status 62 gemcitabine carboplatin 62 QTcF 62 placebo dexamethasone 62 methotrexate monotherapy 62 Scale EDSS 62 achieved ACR# 62 Doxil ® 62 dosing cohorts 62 FDG-PET/CT 62 CIMZIA ™ 62 CHOP chemotherapy 62 response CCyR 62 ug kg 62 log# reduction 62 mcg kg 62 PSADT 62 preoperative chemotherapy 62 achieved sustained virologic 62 melphalan prednisone 62 mg BID 62 #mg dose [002] 62 EDSS score 62 KRAS mutations occur 62 PEG IFN 62 confirmed CCyR 61 PegIFN RBV 61 clinically meaningful improvement 61 heavily pretreated 61 neoadjuvant 61 HBeAg positive patients 61 chemoradiation 61 Median PFS 61 virologic responses 61 postoperative chemotherapy 61 locoregional 61 IV NSCLC 61 virological response 61 Median progression 61 renal tumors 61 Allovectin 7 ® 61 DAS# [002] 61 8mg/kg 61 ribavirin RBV 61 Kaplan Meier estimates 61 secondary efficacy endpoint 61 tumor histology 61 PRECiSE 61 #mg/m# [001] 61 cytogenetic responses 61 endoscopic remission 61 microbiologically evaluable 61 achieved sustained virological 61 FOLFIRI 61 FOLFOX6 61 HCV genotype 61 debulking surgery 61 Bezielle 61 tipranavir ritonavir 61 chemoradiation therapy 61 serum HCV RNA 61 baseline LDH 61 F FDG PET 61 galiximab 61 stage IIIB 61 MADRS score 61 prior chemotherapy regimens 61 papillary renal cell carcinoma 61 Follicular Lymphoma 61 hepatic metastases 61 tumor regressions 61 comparator arm 61 certolizumab 61 detectable HCV RNA 61 nab paclitaxel 61 annualized relapse 61 SVR# 61 radical nephrectomy 61 corticosteroid dose 60 Kaplan Meier method 60 median survivals 60 splenectomized patients 60 mg ustekinumab 60 antiangiogenic therapy 60 visceral metastases 60 histologically proven 60 ACR# responses 60 mg QD 60 carboplatin paclitaxel 60 IU ml 60 differentiated thyroid 60 previously untreated follicular 60 pancreatic adenocarcinoma 60 teriflunomide 60 Secondary endpoints 60 breast carcinoma 60 dimensional echocardiography 60 low dose cytarabine 60 IIIB NSCLC 60 metastatic GIST 60 peginterferon 60 resectable 60 estramustine 60 MabCampath 60 prospectively stratified 60 mg m² 60 TMC# r 60 HBeAg negative patients 60 systemic ALCL 60 cytoreduction 60 alicaforsen enema 60 Primary endpoints 60 4mg/kg 60 Secondary endpoints included 60 hematologic 60 mCRC patients 60 % CI #.#-#.# [005] 60 Fludara 60 chemo radiotherapy 60 HBeAg negative 60 mcg BID 60 HCV SPRINT 60 ZACTIMA 60 oral FTY# 60 telaprevir dosed 60 elevated ALT 60 clinically meaningful improvements 60 mg/m2 60 sUA 60 ER CHOP 60 clodronate 60 peginterferon alfa 2a #KD 60 PASI scores 60 mRCC 60 peginterferon alfa 2a 60 Folfox 60 neoadjuvant treatment 60 mitoxantrone 60 null responders 60 recurrent GBM 60 interferon ribavirin 60 mg BID dose 60 CSBM 60 sustained virologic response 59 univariate 59 crizotinib PF # 59 pegylated alpha interferon 59 rituximab refractory 59 localized renal 59 genotypic resistance 59 5-FU/LV 59 FluCAM arm 59 seroprotection 59 desvenlafaxine succinate 59 PROMACTA 59 tumor progression TTP 59 Median survival 59 estimated GFR 59 androgen suppression 59 mucosal healing 59 Kaplan Meier 59 PROCHYMAL 59 pegylated liposomal doxorubicin 59 alemtuzumab treated 59 hematologic toxicity 59 VGPR 59 ribavirin therapy 59 splenectomized 59 dose cohorts 59 APTIVUS r 59 FOLFIRI alone 59 CIN3 59 octreotide LAR 59 thymoma 59 rFSH 59 operable breast cancer 59 modified RECIST criteria 59 infliximab monotherapy 59 gemcitabine cisplatin 59 DLTs 59 logistic regression analysis 59 Secondary efficacy endpoints 59 ErbB2 positive 59 pegylated interferon alfa 59 dosage regimens 59 dasatinib 59 null responder HCV 59 #mg BID [001] 59 stage IIIA 59 5-fluorouracil/leucovorin 59 CLL SLL 59 FOLPI regimen 59 antiretroviral naïve 59 rindopepimut 59 dacarbazine 59 retrospective cohort 59 huN# DM1 59 lopinavir r arm 59 preoperative PSA 59 #mg/m# [002] 59 FLT3 ITD 59 pT2 59 ug dose 59 alfa 2a 59 oral allopurinol 59 distant metastasis 59 HER2 overexpression 59 posttreatment 59 cisplatin chemotherapy 59 definite stent thrombosis 59 MGd 59 radiotherapy RT 59 LPV r 59 follicular NHL 59 curative resection 59 VELCADE melphalan 59 platinum refractory 59 CMV disease 59 composite endpoint 59 adalimumab 59 plasma uric acid 59 liver histology 59 moderately emetogenic 59 generalized edema 59 #Gy 59 CDAI 59 mg kg cohorts 59 mycophenolate mofetil 59 KRAS wild 59 achieved PASI 59 relapsing multiple sclerosis 59 plus methotrexate 59 pT3 59 radiographic progression 59 postintervention 59 hepatorenal syndrome 59 Pegasys plus Copegus 59 CIMZIA TM certolizumab pegol 59 TLUS 59 rapid virologic response 59 ertapenem 58 cisplatin vinorelbine 58 tumor recurrence 58 q#d 58 histological subtype 58 BCG refractory 58 macroalbuminuria 58 XELOX 58 piperacillin tazobactam 58 ALT flares 58 chemotherapy docetaxel 58 clinicopathological features 58 induction regimen 58 metastatic CRC 58 histologies 58 Peg IFN 58 T1c 58 estimated glomerular filtration 58 GnRH agonist 58 refractory AML 58 PSMA ADC 58 Adjuvant chemotherapy 58 doxorubicin docetaxel 58 mutated KRAS 58 â ‰ ¥ 58 Aflibercept 58 rapid virological response 58 DOXIL 58 pomalidomide 58 hepatitis C genotype 58 cytologically confirmed 58 peg IFN 58 severe exacerbations 58 DLQI 58 UPDRS scores 58 -#.# log# 58 Engerix B 58 decitabine 58 Ceplene/IL-2 58 REYATAZ r arm 58 TIMP 1 58 tumor necrosis 58 RGT arm 58 plus ribavirin 58 Psoriasis Area 58 adjunctive placebo 58 adjuvant GIST 58 liver transplant recipients 58 HER2 positive metastatic breast 58 TACE 58 virologic breakthrough 58 metastatic malignant 58 squamous histology 58 virologic response 58 hepatectomy 58 CLARITY study 58 YERVOY 58 mCi 58 Relapsing remitting MS 58 QRS duration 58 TURBT 58 morphometric vertebral fractures 58 CAMMS# 58 hemagglutination inhibition 58 virologic suppression 58 phase IIb study 58 microgram kg 58 adjuvant cisplatin 58 secondary efficacy endpoints 58 serum HBV DNA 58 baseline HbA1c 58 glycated hemoglobin levels 58 histologically 58 azacytidine 58 Multivariate analysis 58 BEACOPP 58 log# copies mL 58 immunosuppressive regimen 58 leukemia AML 58 clinico pathological 58 mcg Albuferon 58 receiving highly emetogenic 58 refractory NSCLC 58 HCV RESPOND 2 58 atazanavir ritonavir 58 pegylated interferon alpha 58 lymphocyte count 58 recurrent metastatic 58 anemia hemoglobin 58 pertuzumab 58 NATRECOR R 58 recurrent NSCLC 58 FDG PET 58 PREZISTA r 58 relapsed CLL 58 metastatic renal cell carcinoma 58 refractory CLL 58 plus prednisone 58 HSCT 58 LEXIVA r 58 serum urate 58 antibody titer 58 μg dose 58 adefovir treated 58 bowel resection 58 CTEPH 58 Index CDAI score 58 unresectable stage 58 peripheral blood mononuclear 58 lenalidomide Revlimid R 58 pimecrolimus cream 58 chronic HCV genotype 58 -#.# log# copies mL 58 peginterferon alfa 2b 58 haematologic 57 univariate analysis 57 leukocyte count 57 adenotonsillectomy 57 NLX P# 57 epithelial ovarian cancer 57 dosing cohort 57 ARB telmisartan 57 μg doses 57 oral diclofenac 57 multivariate Cox 57 #mg q8h 57 IMGN# 57 liver metastases 57 response pCR 57 ≥ 57 mCi kg 57 ischemic cardiomyopathy 57 relapsed multiple myeloma 57 Tumor Response 57 GOUT 57 NNT = 57 seropositivity 57 Castration Resistant Prostate Cancer 57 Aptivus ® 57 surgical debulking 57 p = #.# [003] 57 mg administered orally 57 angiographic outcomes 57 recurrent VTE 57 EGFR mutation positive 57 NIHSS 57 GLIADEL R Wafer 57 cinacalcet 57 HBV DNA levels 57 virologic 57 febrile neutropenia 57 intravitreal injection 57 rFVIIa 57 operable pancreatic cancer 57 ara C 57 parathyroidectomy 57 Natalizumab 57 extracolonic findings 57 glufosfamide 57 relapsed refractory multiple myeloma 57 ixabepilone 57 mg qd 57 docetaxel chemotherapy 57 resected pancreatic cancer 57 NIHSS score 57 CAELYX 57 Timed Walk 57 log# IU mL 57 #mg/day [002] 57 rALLy trial 57 undetectable virus HCV 57 metastatic malignant melanoma 57 xenograft models 57 recovery CRp 57 Y BOCS 57 nephrectomy 57 VcMP 57 abacavir lamivudine 57 fluoropyrimidine 57 advanced hepatocellular carcinoma 57 placebo controlled clinical trials 57 Operative mortality 57 IFN alfa 57 clinically localized prostate 57 malignant lymphoma 57 #mg BID [003] 57 creatinine clearance 57 calculated creatinine clearance 57 prior relapsers 57 serum phosphorus 57 remission induction 57 XIENCE V PROMUS Stent 57 Raptiva r 57 posttransplant 57 BRIM2 57 Elitek 57 underwent liver transplantation 57 bacillus Calmette Guerin 57 corticosteroids immunoglobulins 57 Xelox 57 primary humoral immunodeficiency 57 postmenopausal osteoporotic women 57 μg kg 57 Thrombolysis 57 tumor resection 57 Score DAS# 57 FDG PET imaging 57 irinotecan chemotherapy 57 icatibant 57 mitomycin 57 nonmetastatic 57 oral Hycamtin 57 virological failure 57 glomerular filtration 57 imatinib 57 interquartile range 57 DAPT 57 paclitaxel Taxol R 57 adverse cytogenetics 57 chronic GVHD 57 prospectively randomized 57 metastatic HRPC 57 cervical carcinoma 57 prior antiangiogenic therapy 57 EGFR expressing mCRC 57 relapsed refractory 57 symptomatic VTE 57 Amrubicin 57 specific antigen PSA 57 Brief Psychiatric 57 Taxotere ® 57 R0 resection 57 mcg dose 57 IFN α 57 leukemia APL 57 pericardial effusion 57 papillary thyroid carcinoma 57 q8h 57 NSABP B 57 Virologic 57 colorectal liver metastases 57 ipsilateral breast 57 doxorubicin cyclophosphamide 57 treatment naïve genotype 57 malignant pleural mesothelioma 57 microbiological eradication 57 refractory multiple myeloma 57 FOLFIRINOX 57 mcg doses 57 achieve sustained virologic 57 stage IIIb 57 MVax R 57 prednisone prednisolone plus 57 mg Proellex 57 MAGE A3 ASCI 57 #F FDG PET 57 hematologic adverse 57 Ejection Fraction 57 complete Early Virological 57 serum antibody 57 Hurthle cell 57 standard chemotherapy regimen 57 BENICAR 57 ARCOXIA 57 nilotinib 57 docetaxel prednisone 57 lymphadenectomy 57 CIN2 + 57 Score TOS 57 hours postdose 57 EXJADE 57 DAS# scores 57 mL/min/#.# m2 57 interferon alfa 57 COPAXONE R 57 Pemetrexed 57 BCIRG 57 ritonavir boosted 57 conditional logistic regression 57 cGy 56 BENICAR HCT 56 Severity Index PASI 56 Cardiopulmonary bypass 56 oral rivaroxaban 56 Hb A1C 56 liver resection 56 HAM D# scores 56 Surgical resection 56 relapsed SCLC 56 vismodegib 56 dasatinib Sprycel ® 56 CVP chemotherapy 56 mitoxantrone chemotherapy 56 adalimumab Humira 56 imatinib therapy 56 oxycodone CR 56 5FU 56 noninferiority 56 KRAS mutations 56 HER2 expression 56 pharmacodynamic PD 56 FDG PET scans 56 Subgroup analyzes 56 Severity MSCS score 56 pmol L 56 HIV RNA 56 rosuvastatin #mg 56 secondary endpoint 56 APPRAISE 56 radioiodine therapy 56 GAMMAGARD 56 multivariate analyzes 56 Newly Diagnosed Multiple Myeloma 56 gout flares 56 completely resected 56 ibandronate 56 moderate renal impairment 56 sunitinib 56 #mg/day [001] 56 FluCAM 56 nonresponders 56 HAQ DI 56 dose escalation 56 ascending dose 56 mcg QD 56 randomized multicenter trial 56 alanine aminotransferase ALT 56 biologic DMARD 56 TTF Therapy 56 mL/min/#.# m 2 56 monoinfected patients 56 pain palliation 56 ALND 56 COPD exacerbation 56 % CI #.#-#.# [006] 56 non splenectomized 56 Enzastaurin 56 Cimzia TM 56 dacarbazine chemotherapy 56 Subgroup analysis 56 HUMIRA achieved PASI 56 Unified Parkinson Disease 56 oral ridaforolimus 56 coinfected patients 56 receiving VICTRELIS 56 Zometa hazard 56 histologic subtype 56 ABVD 56 recurrent glioblastoma 56 metastatic colorectal carcinoma 56 pretreatment serum 56 Stage IIB 56 concurrent chemoradiation 56 R# #mg BID 56 PREZISTA ritonavir 56 % CI #.#-#.# [008] 56 hemoglobin A1c levels 56 cytogenic 56 paclitaxel cisplatin 56 malignant neoplasm 56 Decitabine 56 pegylated IFN 56 ipsilateral stroke 56 indolent NHL 56 mITT population 56 severe neutropenia 56 surgically resectable 56 log# 56 ZOLINZA 56 glioblastoma multiforme GBM 56 low dose dexamethasone 56 XIENCE V demonstrated 56 placebo controlled clinical 56 dose dexamethasone 56 stratifying patients 56 dose melphalan 56 adjunctive ABILIFY 56 stage IIIb IV 56 STRIDE PD 56 serum aminotransferase levels 56 mitoxantrone plus 56 intravenous diuretics 56 q#h 56 subcutaneous PRO 56 DMARD 56 baseline FEV 56 efficacy endpoint 56 taxane chemotherapy 56 nonoperative 56 bendamustine 56 perioperative complications 56 metastatic renal cell 56 paclitaxel carboplatin 56 postoperative complication 56 recurrent malignant glioma 56 SUVmax 56 Scale EDSS score 56 intracranial hemorrhage ICH 56 randomized controlled trials RCTs 56 Virulizin ® 56 preintervention 56 IRLS score 56 multivariable logistic regression 56 HBeAg positive 56 OGTT 56 oral clodronate 56 tipranavir r 56 SLN biopsy 56 goserelin 56 PREZISTA r arm 56 #mg BID [002] 56 HIV HCV coinfected 56 cyclophosphamide doxorubicin vincristine 56 weekly intravenous infusions 56 adriamycin 56 fluticasone salmeterol 56 lumiliximab 56 undetectable viral load 56 efficacy evaluable 56 VFEND 56 somatostatin analog 56 cisplatin gemcitabine 56 allogeneic SCT 56 timepoint 56 Pharmacokinetics PK 56 fludarabine cyclophosphamide 56 CANCIDAS 56 recurrent genital herpes 56 PEGylated interferon beta 1a 56 tumor lysis syndrome 56 genotype 1b 56 pegylated interferon 56 cancer mCRC 56 HBeAg 56 administered subcutaneously 56 unstable angina pectoris 56 ALT elevation 56 distant metastases 56 Change PGIC 56 prespecified secondary 56 aminotransferase levels 56 advanced adenoma 56 amoxicillin clavulanate 56 postprocedure 56 concurrent chemoradiotherapy 56 Cimzia ® certolizumab pegol 56 adjuvant tamoxifen 56 invasive aspergillosis 56 azacitidine 56 trabectedin 56 nondiabetic patients 56 LUX Lung 56 lopinavir r 56 INC# 56 Scale cognitive subscale 56 adjuvant systemic 56 Cardiorespiratory fitness 56 PEG interferon 56 experienced virologic failure 56 colorectal carcinoma 56 IV bolus 56 intradermal injections 56 dosing intervals 56 mg/m2 administered 56 carcinoid 56 K ras mutations 56 eribulin mesylate 56 null responder 56 ULORIC 56 tanespimycin 56 placebo PBO 56 boosted protease inhibitor 56 Dacogen decitabine 56 lamivudine monotherapy 56 ACR# ACR# 56 nicardipine 56 Baseline characteristics 56 MACCE 56 renal cell carcinomas 56 Thal Dex 56 relapsed myeloma 56 metastatic pancreatic 56 naïve HCV 56 CrCl 56 salmeterol fluticasone propionate 56 predefined criteria 56 idiopathic thrombocytopenic purpura 56 Hamilton Anxiety Scale 56 FFNS 56 SCr 56 tapentadol ER 56 adjuvant radiation 56 unresectable 56 anaplastic astrocytoma AA 56 #mg QD [001] 56 binary restenosis 56 nucleoside naive 56 hour bronchodilation 56 SLNB 56 vandetanib 56 paliperidone ER 56 ispinesib administered 55 Tumor shrinkage 55 hormone receptor status 55 HORIZONS AMI trial 55 logistic regression models 55 HCV genotype 1 55 cytoreductive surgery 55 TIMP 55 transaminase levels 55 graft dysfunction 55 APTIVUS 55 liposomal doxorubicin 55 BEXXAR Therapeutic Regimen 55 vincristine doxorubicin 55 nonmetastatic prostate cancer 55 lymph node metastases 55 abiraterone acetate 55 antibody MAb 55 bortezomib 55 lymphopenia 55 methotrexate therapy 55 statistical significance p 55 nonvertebral fractures 55 abnormal cytology 55 HOMA IR 55 virologic response EVR 55 oblimersen 55 PCI ExTRACT TIMI 55 lung metastases 55 p = .# [002] 55 PNH patients 55 serum cortisol 55 adjuvant chemotherapy 55 viral kinetic 55 plus MTX 55 lamivudine refractory patients 55 Ph + 55 statistically significant p = 55 prostate cancer PCa 55 riociguat 55 APTIVUS R 55 gefitinib Iressa 55 T1a 55 telaprevir dosing 55 immunomodulatory therapy 55 metastatic lesion 55 HER2 positive cancers 55 metastatic lung cancer 55 Non inferiority 55 #.#ng/ml 55 serum phosphate 55 NIH CPSI 55 autologous SCT 55 multiple myeloma MM 55 adenoma recurrence 55 n = 55 posaconazole 55 ACZ# 55 HER2 negative 55 nonoperative treatment 55 Kaplan Meier survival 55 OvaRex MAb 55 mCi m 2 55 multicenter Phase 55 DEB# 55 thoracoscopic lobectomy 55 prospective multicentre 55 histopathologic 55 limiting toxicity 55 temsirolimus 55 spirometric 55 alteplase 55 refractory metastatic 55 gastroduodenal 55 fluorouracil 55 eGFR 55 PCWP 55 gemcitabine chemotherapy 55 hepatocellular carcinomas 55 cells mcL 55 lenalidomide dexamethasone 55 relapsing MS 55 serum clusterin levels 55 plus gemcitabine 55 tolerated dose MTD 55 baminercept 55 thalidomide Thalomid 55 docetaxel pretreated 55 EOquin TM 55 confidence interval CI 55 bortezomib Velcade R 55 urothelial carcinoma 55 multivariable analysis 55 EGFR TKI 55 gastric adenocarcinoma 55 TroVax ® 55 androgen deprivation 55 mg TID 55 evaluating REVLIMID 55 custirsen 55 immunostaining 55 neutropaenia 55 elevated LDH 55 intravenous bolus 55 oral antidiabetic medication 55 Myelodysplastic Syndrome 55 graft occlusion 55 histologic 55 diagnosed multiple myeloma 55 ABC/3TC 55 Ishak fibrosis score 55 androgen ablation 55 HBeAg + 55 refractory acute myeloid 55 dacarbazine DTIC 55 IIa trial 55 Degarelix 55 IOP lowering 55 postoperative mortality 55 pharmacokinetic parameters 55 cystectomy 55 Montgomery Åsberg Depression 55 molecular remissions 55 TORISEL 55 nodal metastasis 55 Acute Myeloid Leukaemia AML 55 RRMS patients 55 HGPIN 55 Capacity FVC 55 trials RCTs 55 Hycamtin ® 55 receiving golimumab 55 reduce serum phosphate 55 refractory CTCL 55 point Likert scale 55 MVax 55 HbA 1c levels 55 interferon alfa 2b 55 postoperative radiotherapy 55 spontaneous bowel movements 55 myocardial viability 55 NSTEMI 55 efavirenz EFV 55 external beam radiotherapy 55 salmeterol fluticasone 55 total thyroidectomy 55 achieved statistical significance 55 ascending doses 55 pediatric acute lymphoblastic 55 STELARA 55 Anaplastic 55 SSc 55 glycosylated hemoglobin HbA1c 55 antithymocyte globulin 55 EDEMA4 trial 55 hematopoietic cancers